当前位置：
X-MOL 学术
›
JACC Cardiovasc. Imaging
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Adding Alirocumab to Rosuvastatin Helps Reduce the Vulnerability of Thin-Cap Fibroatheroma: An ALTAIR Trial Report
JACC: Cardiovascular Imaging ( IF 12.8 ) Pub Date : 2020-03-18 , DOI: 10.1016/j.jcmg.2020.01.021 Yoichiro Sugizaki , Hiromasa Otake , Hiroyuki Kawamori , Takayoshi Toba , Yuichiro Nagano , Yoshiro Tsukiyama , Ken-ichi Yanaka , Hiroyuki Yamamoto , Akira Nagasawa , Hiroyuki Onishi , Ryo Takeshige , Shinsuke Nakano , Yoichiro Matsuoka , Kosuke Tanimura , Yu Takahashi , Yusuke Fukuyama , Toshiro Shinke , Tatsuro Ishida , Ken-ichi Hirata
JACC: Cardiovascular Imaging ( IF 12.8 ) Pub Date : 2020-03-18 , DOI: 10.1016/j.jcmg.2020.01.021 Yoichiro Sugizaki , Hiromasa Otake , Hiroyuki Kawamori , Takayoshi Toba , Yuichiro Nagano , Yoshiro Tsukiyama , Ken-ichi Yanaka , Hiroyuki Yamamoto , Akira Nagasawa , Hiroyuki Onishi , Ryo Takeshige , Shinsuke Nakano , Yoichiro Matsuoka , Kosuke Tanimura , Yu Takahashi , Yusuke Fukuyama , Toshiro Shinke , Tatsuro Ishida , Ken-ichi Hirata
Large randomized controlled trials demonstrated that adding anti–proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statins improved clinical outcomes. Compared with statin monotherapy, the use of PCSK9 inhibitors with statins significantly reduced the incidence of acute
中文翻译：
在瑞舒伐他汀中添加 Alirocumab 有助于降低薄帽纤维粥样瘤的脆弱性：ALTAIR 试验报告
大型随机对照试验表明，在他汀类药物中添加抗前蛋白转化酶枯草杆菌蛋白酶/kexin 9 (PCSK9) 抑制剂可改善临床结果。与他汀类药物单药治疗相比，PCSK9抑制剂与他汀类药物联合使用显着降低了急性发作的发生率。
更新日期：2020-03-18
中文翻译：
在瑞舒伐他汀中添加 Alirocumab 有助于降低薄帽纤维粥样瘤的脆弱性：ALTAIR 试验报告
大型随机对照试验表明，在他汀类药物中添加抗前蛋白转化酶枯草杆菌蛋白酶/kexin 9 (PCSK9) 抑制剂可改善临床结果。与他汀类药物单药治疗相比，PCSK9抑制剂与他汀类药物联合使用显着降低了急性发作的发生率。
京公网安备 11010802027423号